Boan Biotech - Public Comps and Valuation Multiples

Boan Biotech Overview

About Boan Biotech

Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. The company is engaged in the development, manufacture, and commercialization of high-quality biologics in China and around the world. It focuses on areas such as oncology, metabolism, autoimmunity, metabolism, and ophthalmology. Geographically company's revenue is generated from customers located in Mainland China.

Founded

2013

HQ

Employees

760

Website

boan-bio.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $127M

LTM EBITDA $33.7M

EV

$933M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Boan Biotech Financials

As of September 2025, Boan Biotech reported last 12-month revenue of $127M and EBITDA of $33.7M.

In the same period, Boan Biotech generated $95.4M in LTM gross profit and $15.7M in net income.

See Boan Biotech valuation multiples based on analyst estimates

Boan Biotech P&L

In the most recent fiscal year, Boan Biotech reported revenue of $93.4M and EBITDA of $23.0M.

Boan Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Boan Biotech valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$127M	XXX	$93.4M	XXX	XXX	XXX
Gross Profit	$95.4M	XXX	$69.8M	XXX	XXX	XXX
Gross Margin	75%	XXX	75%	XXX	XXX	XXX
EBITDA	$33.7M	XXX	$23.0M	XXX	XXX	XXX
EBITDA Margin	27%	XXX	25%	XXX	XXX	XXX
EBIT	$17.1M	XXX	$13.4M	XXX	XXX	XXX
EBIT Margin	13%	XXX	14%	XXX	XXX	XXX
Net Profit	$15.7M	XXX	$9.4M	XXX	XXX	XXX
Net Margin	12%	XXX	10%	XXX	XXX	XXX
Net Debt	XXX	XXX	$61.7M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Boan Biotech including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $127M. EBITDA for the last twelve months was $33.7M. In the most recent fiscal year, Boan Biotech achieved $93.4M in revenue and $23.0M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$127M	Analyst estimates available to subscribers	$93.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$95.4M	Analyst estimates available to subscribers	$69.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	75.4% gross margin	Analyst estimates available to subscribers	74.7% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$33.7M	Analyst estimates available to subscribers	$23.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	26.6% EBITDA margin	Analyst estimates available to subscribers	24.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$17.1M	Analyst estimates available to subscribers	$13.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	13.5% EBIT margin	Analyst estimates available to subscribers	14.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$15.7M	Analyst estimates available to subscribers	$9.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	12.4% net profit margin	Analyst estimates available to subscribers	10.1% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$61.7M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Boan Biotech

This financial data table provides comprehensive performance metrics for Boan Biotech, a company based in Hong Kong. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Boan Biotech generated $127M in revenue over the last twelve months.
The company achieved $33.7M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $95.4M.
Net income over the last twelve months reached $15.7M.

Fiscal Year Performance

In the most recent fiscal year, Boan Biotech reported $93.4M in total revenue.
Fiscal year EBITDA was $23.0M.
The company maintained a gross profit margin of 74.7% in the most recent fiscal year.
EBITDA margin for the fiscal year was 24.6%.
Net profit margin reached 10.1% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Boan Biotech. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Boan Biotech Stock Performance

Boan Biotech has current market cap of HKD 7.1B (or $914M), and EV of HKD 7.3B (or $933M).

Market Cap Evolution

Boan Biotech Stock Data

As of October 17, 2025, Boan Biotech's stock price is HKD 11 (or $1).

See Boan Biotech trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$933M	$914M	XXX	XXX	XXX	XXX	$0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Boan Biotech Valuation Multiples

Boan Biotech's trades at 10.0x EV/Revenue multiple, and 40.6x EV/EBITDA.

See valuation multiples for Boan Biotech and 15K+ public comps

Boan Biotech Financial Valuation Multiples

As of October 17, 2025, Boan Biotech has market cap of $914M and EV of $933M.

Equity research analysts estimate Boan Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Boan Biotech has a P/E ratio of 63.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$914M	XXX	$914M	XXX	XXX	XXX
EV (current)	$933M	XXX	$933M	XXX	XXX	XXX
EV/Revenue	8.0x	XXX	10.0x	XXX	XXX	XXX
EV/EBITDA	30.2x	XXX	40.6x	XXX	XXX	XXX
EV/EBIT	59.7x	XXX	69.5x	XXX	XXX	XXX
EV/Gross Profit	10.7x	XXX	n/a	XXX	XXX	XXX
P/E	63.7x	XXX	97.1x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-15.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Boan Biotech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Boan Biotech Margins & Growth Rates

Boan Biotech's last 12 month revenue growth is 12%

Boan Biotech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Boan Biotech's rule of 40 is 9% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Boan Biotech's rule of X is 57% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Boan Biotech and other 15K+ public comps

Boan Biotech Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	12%	XXX	19%	XXX	XXX	XXX
EBITDA Margin	27%	XXX	25%	XXX	XXX	XXX
EBITDA Growth	13%	XXX	n/a	XXX	XXX	XXX
Rule of 40	9%	XXX	37%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	57%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	39%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	21%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	60%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial